當(dāng)前位置：首頁 JCRQ1 期刊介紹(非官網(wǎng))

Dermatology And TherapySCIE

國(guó)際簡(jiǎn)稱：DERMATOLOGY THER 參考譯名：皮膚科和治療

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：2193-8210; E-ISSN：2190-9172; 是否OA：開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：Germany; 出版商：Springer Healthcare; 出版語言：English; 出版周期：12 issues per year; 出版年份：2011; 研究方向：Medicine-Dermatology

評(píng)價(jià)信息：: 影響因子：3.5; CiteScore指數(shù)：6; SJR指數(shù)：1.424; SNIP指數(shù)：1.328

發(fā)文數(shù)據(jù)：: Gold OA文章占比：98.75%; 研究類文章占比：75.94%; 年發(fā)文量：187; 自引率：0.0882...; 開源占比：0.992; 出版撤稿占比：0; 出版國(guó)人文章占比：0.04; OA被引用占比：1

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Dermatology And Therapy期刊介紹

Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.

Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.

The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.

期刊簡(jiǎn)介Dermatology And Therapy期刊介紹

《Dermatology And Therapy》自2011出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間： 6 Weeks
醫(yī)學(xué)
DERMATOLOGY
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Dermatology And Therapy Cite Score數(shù)據(jù)

CiteScore：6
SJR：1.424
SNIP：1.328

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Dermatology	Q1	17 / 142	88%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Dermatology And Therapy 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	DERMATOLOGY 皮膚病學(xué)	3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Dermatology And Therapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：DERMATOLOGY	SCIE	Q1	20 / 94	79.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：DERMATOLOGY	SCIE	Q1	19 / 94	80.32%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA108
Italy41
Spain28
France27
GERMANY (FED REP GER)26
England22
CHINA MAINLAND18
Poland18
Belgium14
Canada12

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Design of Effisayil (TM) 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis
Author: Morita, Akimichi; Choon, Siew Eng; Bachelez, Herve; Anadkat, Milan J.; Marrakchi, Slaheddine; Zheng, Min; Tsai, Tsen-Fang; Turki, Hamida; Hua, Harry; Rajeswari, Sushmita; Thoma, Christian; Burden, A. David

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 347-359. DOI: 10.1007/s13555-022-00835-6
2、Effect of 30% Supramolecular Salicylic Acid Peel on Skin Microbiota and Inflammation in Patients with Moderate-to-Severe Acne Vulgaris
Author: Shao, Xinyi; Chen, Yangmei; Zhang, Lingzhao; Zhang, Yujie; Ariyawati, Asoka; Chen, Tingqiao; Chen, Jiayi; Liu, Lin; Pu, Yihuan; Li, Yuxin; Chen, Jin

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 155-168. DOI: 10.1007/s13555-022-00844-5
3、Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
Author: Yu, Chen; Wang, Gang; Burge, Russel T.; Ye, Erjia; Dou, Guanshen; Li, Jinnan; Harrison, Ryan W.; McLean, Robert R.; Kerti, Samantha J.; Bagel, Jerry

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 187-206. DOI: 10.1007/s13555-022-00843-6
4、Application of Comfort Therapy under eCASH Concept in Acute and Chronic Wound Treatment
Author: Shi, Shuting; Wei, Jiayu; Lyu, Guozhong; Zhong, Xiaohui; Zhu, Lihong; Yang, Minlie

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 1, pp. 299-314. DOI: 10.1007/s13555-022-00852-5
5、Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
Author: Yang, Jing; Hu, Kun; Li, Xingyu; Hu, Jingjin; Tan, Minjia; Zhang, Mi; Kuang, Yehong; Lv, Chengzhi; Chen, Junchen

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 477-485. DOI: 10.1007/s13555-022-00869-w
6、Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
Author: Jiang, Congjun; Zhou, Huan; Zhang, Wanlu; Xia, Yu; Li, Baiyong; Ni, Xiang; Wang, Guoqin; Zhang, Wenhui; Chen, Benchao; He, Zhimei; Zhang, Min; Chen, Rui; Jin, Hongzhong; Deng, Liehua

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 555-567. DOI: 10.1007/s13555-022-00880-1
7、An Intelligent Diagnostic Model for Melasma Based on Deep Learning and Multimode Image Input
Author: Liu, Lin; Liang, Chen; Xue, Yuzhou; Chen, Tingqiao; Chen, Yangmei; Lan, Yufan; Wen, Jiamei; Shao, Xinyi; Chen, Jin

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 2, pp. 569-579. DOI: 10.1007/s13555-022-00874-z
8、Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective
Author: Chu, Chia-Yu; Yao, Tsung-Chieh; Shih, I. -Hsin; Yang, Chin-Yi; Chin, Chan Lee; Ibrahim, Sabeera Begum Binti Kader; Thevarajah, Suganthi; Fon, Leong Kin; Ho, Marco Hok-Kung; Mo, Chow Chung; Yu, Chow Pok; Loo, Steven King-Fan; Luger, Thomas

Journal: DERMATOLOGY AND THERAPY. 2023; Vol. 13, Issue 3, pp. 717-727. DOI: 10.1007/s13555-022-00886-9